Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 439 of 641 · 7,691 filings

  • First Northwest Bancorp (FNWB) FY2024 10-K risk factors
    28 risks

    Concentrated exposure to Washington state real estate markets heavily influences credit risk and earnings potential. Commercial real estate loans total $723.0 million, representing 42.6% of the loan portfolio. Five largest borrowers account for $95.9 million in credit exposure.

    Filed Mar 13, 2025
  • Gossamer Bio (GOSS) FY2024 10-K risk factors
    72 risks

    Company is pre-revenue and clinical-stage, relying heavily on the success, financing, and clinical trials of its lead product candidate, seralutinib.

    Filed Mar 13, 2025
  • GrowGeneration (GRWG) FY2024 10-K risk factors
    38 risks

    GrowGeneration faces concentrated risks from serving the volatile cannabis and hemp industries where federal illegality under the Controlled Substances Act limits banking access and creates regulatory uncertainty. The company struggles with industry downturns leading to store consolidations, staffing reductions, inventory valuation challenges, and goodwill impairment charges.

    Filed Mar 13, 2025
  • Heritage Global (HGBL) FY2024 10-K risk factors
    31 risks

    Specialty Lending segment notes receivable concentration poses a major risk, with one borrower representing 74% of total gross notes.

    Filed Mar 13, 2025
  • Heritage Insurance Holdings (HRTG) FY2024 10-K risk factors
    39 risks

    Loss reserves and catastrophe exposure in coastal states dominate Heritage Insurance Holdings, Inc. operations and risk profile.

    Filed Mar 13, 2025
  • HomeTrust Bancshares (HTB) FY2024 10-K risk factors
    35 risks

    Loan portfolio risks dominate, notably residential mortgages, commercial real estate, equipment finance, and municipal leases.

    Filed Mar 13, 2025
  • Information Services Group (III) FY2024 10-K risk factors
    39 risks

    Interest rate sensitivity and debt covenant compliance constrain our financial liquidity and growth flexibility.

    Filed Mar 13, 2025
  • In8bio (INAB) FY2024 10-K risk factors
    78 risks

    Substantial doubt about going concern threatens continued operations without significant additional capital raising.

    Filed Mar 13, 2025
  • Indaptus Therapeutics (INDP) FY2024 10-K risk factors
    53 risks

    Clinical-stage biotechnology company focused on developing systemically-administered anti-cancer and anti-viral immunotherapy candidates, primarily Decoy20.

    Filed Mar 13, 2025
  • Intensity Therapeutics (INTS) FY2024 10-K risk factors
    57 risks

    The company faces severe going concern doubts, zero product revenues, heavy reliance on a single intratumoral technology, and the need for substantial additional financing.

    Filed Mar 13, 2025
  • Intest (INTT) FY2024 10-K risk factors
    30 risks

    Semiconductor market cyclicality and supply chain constraints dominate the risk profile. Acquisition growth brings integration challenges and financing costs. Geopolitical tensions in China, Taiwan, Ukraine, and Israel threaten operations. Customer concentration and international revenue expose the company to localized downturns.

    Filed Mar 13, 2025
  • KLX Energy Services Holdings (KLXE) FY2024 10-K risk factors
    53 risks

    The risk section is dominated by commodity price volatility, customer concentration, and heavy debt obligations.

    Filed Mar 13, 2025

Companies covered

4,011 companies

371 more under A